PMN

ProMIS Neurosciences Inc. (PMN) | Rumor.io

ProMIS Neurosciences

PMN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,801

Bullish sentiment (50-day avg)86%

Price to earnings ratio7.78

Market capitalization95.5M

Earnings per share-12.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-39.7M

Social

What share of all stock conversation is about PMN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 29

$PMN has brought a level of rigor and honesty to the AD therapeutic market, setting itself apart from other companies.
ProMIS Neurosciences, Inc. ($PMN) will present Phase 1 Alzheimer's Disease results for PMN-310 in 1Q27.
A recent analyst rating from Guggenheim raised the price target for $PMN to $69.

Generated by AI

Sentiment

Of the messages about PMN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	77.78% -22.22	85.82% +11.24
Bearish	—	—	22.22% +22.22	14.18% -11.24

Bullish· Jan 30

The company has secured a significant $175 million private placement financing, providing financial stability for at least 2 years.
Insiders have increased their ownership stake by 50% after purchasing 750k shares of the initial 7mil issued, indicating their confidence in the efficacy of PMN310.
The asset is setting up nicely for continuation, with price consolidating near highs, often leading to another push higher.

Bearish· Jan 30

The company's existing shareholders have been diluted significantly.
Short sellers are very active and appear to be dominating the stock.
The stock's price increase is likely due to the sale of shares through a PIPE financing, which will eventually be sold, causing the price to drop.

Generated by AI

Topics

Of the messages about PMN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	77.39%
Technical Analysis	—	—	0%	14.84%
Analysts	—	—	0%	7.07%
Controversies	—	—	0%	0.71%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jan 30

ProMIS Neurosciences, Inc. announced a private placement financing of up to $175 million, with $75 million upfront and an additional $100 million possible from warrant exercise.
The company sold approximately 6.8 million common shares and 6.9 million warrants, with pricing at $10.77 for most shares and $12.13 for insiders and affiliates.
The financing is expected to support the development of antibody therapeutics and vaccines targeting neurodegenerative diseases, such as Alzheimer's.

Technical Analysis· Jul 21

The analyst believes ProMIS Neurosciences, Inc. ($PMN) is forming a bullish divergence, indicating a potential price increase to $1.60.
The target price for $PMN has been set at $2.00, with a possible squeeze above $1.6, according to the analyst's prediction.
The analyst is looking for a close above $1.08 as a confirmation of the bullish trend, with a possible explosive move for AH's and premarket.

Generated by AI

Community

Of the messages about PMN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.44%	31.72%
Newcomers	—	—	26.56%	68.28%

Regulars· Jul 28

ProMIS Neurosciences, Inc. has reported positive blinded six-month interim safety and biomarker data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease trial, with 68.5% of patients showing reductions in disease-relevant biomarkers.
The data show early biomarker movement consistent with target engagement, and experts believe a profile with low incidence of total ARIA would be a game-changer, while plasma pTau217 and CSF MTBR-tau243 are highly encouraging before a definitive readout.
Many regular participants are optimistic about the company's prospects, with some expecting a partnership announcement and others believing the share price estimates are too low, with one participant expressing disappointment with the reporting of the biomarker data.

Newcomers· Jul 28

ProMIS Neurosciences reports positive blinded six-month interim safety and biomarker data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease trial, with no ARIA-E and low total ARIA incidence.
Newcomers are optimistic about the asset's potential, with some predicting a takeover and share price increase to $179-$240.
The asset's positive interim results and analyst upgrades are being seen as a strong indicator of progression and a potential short squeeze.

Generated by AI

News

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings. Conference details below: September 9-11: Cantor Global Healthcare ConferenceLocation: New York, NYFires

29d agoYahoo! Finance Canada

Promis Neurosciences Q2 Earnings Call Highlights

Promis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer’s disease. President and Chief Executive Officer Neil Warma said the company is using i

1mo agoYahoo Finance

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

1mo agoInvesting.com

Also Discussed

Investors talking about PMN also mention

#	Name	Attention
1	Telomir Pharmaceuticals, Inc.TELO	0%0
2	PTL Limited Class A Ordinary SharesPTLE	0%new
3	Above Food Ingredients Inc.ABVE	0%new
4	OneMedNet Corp. Class A Common StockONMD	0%-0.01
5	ProKidney Corp. Class A Ordinary SharesPROK	0%0
6	Adagio Medical Holdings, Inc.ADGM	0%new
7	MKDWELL Tech Inc.MKDW	0%+0
8	Calidi Biotherapeutics, Inc.CLDI	0%0
9	Kairos Pharma Ltd.KAPA	0%new
10	NeurAxis, Inc.NRXS	0%0

ProMIS Neurosciences Inc.

Healthcare
Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases and other misfolded protein disorders. The company works on treatments designed to selectively target toxic protein species linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and multiple system atrophy. Its research platform combines protein biology, physics, and computational methods to identify disease-specific epitopes on misfolded proteins, supporting a pipeline of precision medicine candidates. ProMIS Neurosciences also develops therapies aimed at other central nervous system disorders, reflecting its broader focus on protein misfolding biology in neurological disease. Headquartered in Toronto, Canada, with offices in Cambridge, Massachusetts, ProMIS Neurosciences plays a specialized role in the biotechnology market as a developer of targeted approaches for complex neurological conditions.

Website

Location

1920 Yonge Street

Toronto, ON, M4S 3E2

Canada

Social

What share of all stock conversation is about PMN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 29

$PMN has brought a level of rigor and honesty to the AD therapeutic market, setting itself apart from other companies.
ProMIS Neurosciences, Inc. ($PMN) will present Phase 1 Alzheimer's Disease results for PMN-310 in 1Q27.
A recent analyst rating from Guggenheim raised the price target for $PMN to $69.

Generated by AI

Sentiment

Of the messages about PMN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	77.78% -22.22	85.82% +11.24
Bearish	—	—	22.22% +22.22	14.18% -11.24

Bullish· Jan 30

The company has secured a significant $175 million private placement financing, providing financial stability for at least 2 years.
Insiders have increased their ownership stake by 50% after purchasing 750k shares of the initial 7mil issued, indicating their confidence in the efficacy of PMN310.
The asset is setting up nicely for continuation, with price consolidating near highs, often leading to another push higher.

Bearish· Jan 30

The company's existing shareholders have been diluted significantly.
Short sellers are very active and appear to be dominating the stock.
The stock's price increase is likely due to the sale of shares through a PIPE financing, which will eventually be sold, causing the price to drop.

Generated by AI

Topics

Of the messages about PMN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	77.39%
Technical Analysis	—	—	0%	14.84%
Analysts	—	—	0%	7.07%
Controversies	—	—	0%	0.71%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jan 30

ProMIS Neurosciences, Inc. announced a private placement financing of up to $175 million, with $75 million upfront and an additional $100 million possible from warrant exercise.
The company sold approximately 6.8 million common shares and 6.9 million warrants, with pricing at $10.77 for most shares and $12.13 for insiders and affiliates.
The financing is expected to support the development of antibody therapeutics and vaccines targeting neurodegenerative diseases, such as Alzheimer's.

Technical Analysis· Jul 21

The analyst believes ProMIS Neurosciences, Inc. ($PMN) is forming a bullish divergence, indicating a potential price increase to $1.60.
The target price for $PMN has been set at $2.00, with a possible squeeze above $1.6, according to the analyst's prediction.
The analyst is looking for a close above $1.08 as a confirmation of the bullish trend, with a possible explosive move for AH's and premarket.

Generated by AI

Community

Of the messages about PMN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.44%	31.72%
Newcomers	—	—	26.56%	68.28%

Regulars· Jul 28

ProMIS Neurosciences, Inc. has reported positive blinded six-month interim safety and biomarker data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease trial, with 68.5% of patients showing reductions in disease-relevant biomarkers.
The data show early biomarker movement consistent with target engagement, and experts believe a profile with low incidence of total ARIA would be a game-changer, while plasma pTau217 and CSF MTBR-tau243 are highly encouraging before a definitive readout.
Many regular participants are optimistic about the company's prospects, with some expecting a partnership announcement and others believing the share price estimates are too low, with one participant expressing disappointment with the reporting of the biomarker data.

Newcomers· Jul 28

ProMIS Neurosciences reports positive blinded six-month interim safety and biomarker data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease trial, with no ARIA-E and low total ARIA incidence.
Newcomers are optimistic about the asset's potential, with some predicting a takeover and share price increase to $179-$240.
The asset's positive interim results and analyst upgrades are being seen as a strong indicator of progression and a potential short squeeze.

Generated by AI

ProMIS Neurosciences

Social

Jul 29

Bullish· Jan 30

Bearish· Jan 30

Announcements· Jan 30

Technical Analysis· Jul 21

Regulars· Jul 28

Newcomers· Jul 28

ProMIS Neurosciences at H.C. Wainwright conference: safety stands out

ProMIS Neurosciences at Moody Capital conference: safety sets it apart

ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Promis Neurosciences Q2 Earnings Call Highlights

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

Also Discussed

ProMIS Neurosciences Inc.

Company Information

Location

ProMIS Neurosciences at H.C. Wainwright conference: safety stands out

ProMIS Neurosciences at Moody Capital conference: safety sets it apart

ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Promis Neurosciences Q2 Earnings Call Highlights

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

Also Discussed

Social

Jul 29

Bullish· Jan 30

Bearish· Jan 30

Announcements· Jan 30

Technical Analysis· Jul 21

Regulars· Jul 28

Newcomers· Jul 28